The growth of solid tumours requires a blood supply provided by re-modeling of existing blood vessel endothelium (angiogenesis). Little is known about transcription regulators which are speci®c for the control of tumour angiogenesis. The proto-oncogene LMO2 encodes a LIM domain transcription regulator which controls angiogenesis during mouse embryogenesis where it regulates remodelling of the capillary network into mature vessels. We now show that Lmo2 expression is augmented in tumour endothelium such as mouse thymomas and human lung tumours. The functional signi®cance of this Lmo2 expression was assessed in teratocarcinomas induced in nude mice by subcutaneous implantation of Lmo2-lacZ targeted ES cells. CD31-positive, sprouting endothelium of ES-cell origin occurred in teratocarcinomas from heterozygous Lmo2-lacZ ES cells but none occurred from null Lmo2-lacZ ES cells. Therefore, in this model Lmo2 is an obligatory regulator of neo-vascularization of tumours. These data suggest that LMO2 function may be a drug target in cancer and other conditions characterized by neovascularization.
Introduction
The formation of the vascular system during embryogenesis occurs in two stages. In the ®rst stage or vasculogenesis, de novo endothelial cells dierentiate from mesoderm to create the primary capillary network. In the subsequent stage of angiogenesis, the existing endothelial layers are remodelled to form mature blood vessels and hence the ®nal vasculature of the adult. There are a number of situations in adults where this remodelling process of angiogenesis is required such as wound healing or menstruation and in pathological conditions, such as tumour angiogenesis, ischaemia, in¯ammation and diabetic retinopathy (Folkman, 1995) . In cancer, angiogenesis is a key part of solid tumour growth and invasion (metastasis). Like all cells, cancer cells require oxygen and carbon dioxide exchange, and therefore solid tumours must develop a blood supply to facilitate their growth (Folkman, 1971 (Folkman, , 1972 . This is achieved by subverting local vessel endothelium in the process of tumour angiogenesis (Hanahan and Folkman, 1996; Weidner et al., 1991) which allows for sprouting of existing endothelium into the tumour deposits (Carmeliet and Jain, 2000) . This angiogenic switch occurs when there is a relative increase in angiogenesis stimulating factors and in tumour growth, the cancer cells become angiogenic to stimulate the necessary remodelling state. Furthermore, the concept of mosaic blood vessels is strongly supported by recent data which shows that a signi®cant percentage of the vessel wall can be made from tumour cells (Chang et al., 2000) and these cells are continually shed into the vessel lumen, and therefore the blood circulation contributing to the metastatic population. In addition, so-called angioblast-like endothelial precursors may be recruited from the bone marrow (Ra®i, 2000) providing another source of vessel wall cells. These features of angiogenesis have been proposed as a major target for patient treatment in cancer (Folkman, 1971 (Folkman, , 1972 .
Several key molecules have been identi®ed which control angiogenesis, such as vascular endothelial growth factor (Ferrara and Alitalo, 1999) which stimulates the process of vessel sprouting, but little is known of transcription regulators of vessel remodeling. Some candidates have come from the study of chromosomal translocations in human leukaemias which has led to the identi®cation of novel genes, many of which are transcription factors (reviewed in Rabbitts (1994) ). The LMO2 gene is an example, being a gene discovered from the chromosomal translocation (t(11;14)(p13;q11) in T-cell acute leukaemia (Boehm et al., 1991; Royer-Pokora et al., 1991) . The gene encodes a small protein comprising two zinc-binding LIMdomains and this structural element appears to be a protein interaction domain capable of binding various partners depending on the cellular environment in which it is expressed (Rabbitts, 1998) . For instance, LMO2 can interact with the T-cell oncogenic protein TAL1/SCL in haematopoietic cells and in leukaemias (see (Rabbitts, 1998) ). As with many of the genes activated by chromosomal translocations, the LMO2 function adopted in tumour cells belies its normal function. In the case of Lmo2, gene targeting experiments in mice have shown that it is crucial for haematopoiesis (both primitive and de®nitive) Yamada et al., 1998) and there is a complete failure of adult haematopoiesis in the absence of Lmo2 (Yamada et al., 1998) . In addition, while the yolk sac endothelium appears to develop normally in Lmo2 homozygous null mice , null embryos do not sustain development of a mature blood vascular system because of a speci®c failure of the remodelling of the capillary endothelium into mature vessels (angiogenesis) (Yamada et al., 2000) . LMO2 is therefore a candidate factor for controlling tumour angiogenesis in view of these embryonic roles in blood vessel endothelium. We have now evaluated a possible function of LMO2 in angiogenesis of primary tumours and in tumours implanted in mice. Our data suggest that LMO2 is required for tumour angiogenesis.
Results and Discussion
The expression of Lmo2 has been followed using a gene targeting knock-in strategy in which lacZ was cloned in frame with Lmo2 exon 2 allowing Lmo2 gene expression to be monitored in vivo in mice via bgalactosidase (b-gal) enzyme activity (Yamada et al., 2000) . ES cells were generated with one Lmo2 allele disrupted by this homologous recombination (Lmo2+/7 where the null allele is the lacZ knock-in) ( Figure 1a ) and heterozygous mice carrying this allele have been described (Yamada et al., 2000) . These mice were crossed with tumour-prone p53 null mice (Harvey et al., 1993) to generate p537/7 ; Lmo2+/7 mice, which frequently develop thymomas. When signs of illhealth indicated lymphomatous deposits of sucient size, the mice were sacri®ced and thymomas subjected to whole mount staining. Histological sections of the tumour specimens were obtained and b-gal expression in blood vessel lining was compared with that of normal thymus tissue from Lmo2+/7 mice. This conclusion was con®rmed by examining whether human tumours also exhibit augmented LMO2 expression in endothelium. Lung tumour biopsies and matched peripheral parts of normal lung were used for immunohistochemistry (IHC) with the anti-LMO2 antibody ( Figure 2b ). Sections were made from these specimens and either H&E stained or IHC performed with antibodies detecting the endothelial cell marker CD31 (PECAM) or with antibodies detecting LMO2. The normal and adenocarcinoma blood vessel endothelial cells had equivalent binding with anti-CD31 antibody (Figure 2b , middle sections). However, LMO2 protein was only detected in the lung adenocarcinoma vessels, while it was almost undetectable on normal vessels of lung ( Figure 2b , right hand panel). We have examined two separate adenocarcinomas and two separate squamous cell carcinomas of the lung. Therefore there seems to be augmentation of LMO2 protein in these human lung tumours like that in mouse T-cell lymphomas.
These observations show that LMO2 is expressed in tumour endothelium and that the level appears to be augmented in tumour angiogenic situations. This in turn implies a functional role for LMO2 in tumour angiogenesis. Accordingly, a teratocarcinoma assay was established to determine if the Lmo2 protein is functional in endothelial cells during tumour angiogenesis. An Lmo27/7 ES line has been described in which one null Lmo2 allele carries the lacZ knock-in and the second allele Lmo2 has been targeted by hygromycin insertion (illustrated in Figure 1b ) (Yamada et al., 2000) . Teratocarcinomas were developed by subcutaneous implantation of either Lmo2+/7 or Lmo27/7 ES cells in nude mice. ES cells were injected into both¯anks of a cohort of nude mice and tumours were excised at 2, 3, 3.5 and 4 weeks after implantation for analysis of ES-derived vasculature using b-gal staining for Lmo2-lacZ gene transcription and counter staining with the endothelial cell surface marker CD31. Two issues are pertinent to the interpretation. Firstly, both ES-derived and host (nude mouse) derived vasculature will contribute in this model and secondly b-gal expression will still occur in any Lmo27/7 ES cell derivatives in which the Lmo2-lacZ knock-in gene is transcribed.
In all we examined in detail 19 tumours derived from either Lmo2+/7 or Lmo27/7 targeted ES cells (Table 1) . There appeared to be little signi®cant dierence in the rate of growth of the teratocarcinomas consistent with a blood supply being contributed by angiogenesis from the host endothelium. However, major dierences were observed in the pattern of b-gal expression within the developing tumours. Macroscopic examination of resected tumours using a dissecting microscope, after b-gal staining, showed that after about three weeks, an intrinsic Lmo2+/7 ES cell-derived vascular system was visible and could be distinguished from host (nude mice) vessels because of Lmo2-lacZ fusion protein in endothelial cells of ES cell origin. Two weeks (2W) after implantation, there was no sign of obvious ES cell-derived vascular tree development in either Lmo2+/7 and Lmo27/7 tumours (Figure 3) . However, clusters of lacZ-positive cells, possibly angioblasts or precursors of sprouting endothelium, were present in both sets of tumours. From 2 weeks onwards, vascular trees, displaying (Table 1) . Vascular trees which appeared in Lmo2+/7 tumours kept growing until they formed the more mature vascular system in the tumour at 3.5 weeks and 4 weeks (Figure 3 ). However, there was no ES-derived vascular tree development in Lmo27/7 tumours even at this stage (Figure 3 ). Histological analysis of Lmo2+/7 and Lmo27/7 tumours at 3 ± 4 weeks showed the dierence in the two kinds of ES-derived tumour vasculature in more detail (Figure 4) . In Lmo2+/7 tumours, the development of ES cell intrinsic vascular system was obvious, because the vascular wall cells were mostly b-gal positive (Figure 4 ) and the endothelial nature of these cells were clearly shown by b-gal and CD31 double staining. Although b-gal positive cells were sometimes seen in immature neuroepithelial component, most of them were endothelial cells. On the other hand, in Lmo27/7 tumours, we found b-gal activity was only evident in undierentiated cell clusters which showed little histological sign of dierentiation, other than b-galpositive neuro-epithelial cells (Figure 4 ). The undierentiated cells did not co-express CD31 while CD31-positive endothelial cells in Lmo27/7 tumours were b-gal negative, and thus of host nude mice origin (Figure 4 , lower panels).
Lmo2 was identi®ed as a T-cell oncogene activated by speci®c chromosomal translocations (Rabbitts, 1998) . The gene is normally expressed in endothelial cells of mouse embryos where it is required for angiogenesis after vascularization has occurred (Yamada et al., 2000) . Our results show augmentation of LMO2 expression in tumour neo-vasculature. Furthermore, in the absence of Lmo2, the development of a mature vascular system in solid tumours is prevented in an ES-cell tumour model. Neo-vascularisation is a crucial step in development of several human diseases and the regulation of this process could control these progressive diseases. Although growth factors and their cell surface receptors are important for control of angiogenesis (e.g. vascular endothelial growth factor, angiopoietin, ®broblast growth factor and their cell surface receptors, reviewed in (Carmeliet and Jain, 2000) ) and their clinical application has been extensively studied, the molecular mechanism of transcriptional control of angiogenesis remains unclear. Our (Yamada et al., 2000) . Heterozygous and homozygous null mutations were generated in ES cells to give Lmo2+/7 (called KZ26+/7 in Yamada et al. (2000) ) and Lmo27/7 (called KZ267/7 in Yamada et al. (2000) ). (a) The null allele in Lmo2+/7 cells was made using neomycin selection and caused a fusion of the bacterial lacZ gene with the second exon of Lmo2; this results in a b-galactosidase fusion protein comprising a short stretch of Lmo2 encoded amino acids and the whole b-galactosidase protein (Yamada et al., 2000) . (b) The Lmo2+/7 ES cells (clone KZ26+/7 ) was used for targeting the second Lmo2 allele by insertion of the hygromycin resistance marker ®nding that the LIM-only protein LMO2 is a nuclear regulator of tumour neo-vascularization may help to understand transcription programmes in this process and furthermore highlights a potential therapeutic application to cancer treatment, especially because LMO2 has a speci®c role in neo-vascularization whilst existing endothelial cells do not seem to require the protein.
The LIM domain provides an interface for protein interactions (Schmeichel and Beckerle, 1994; ValgeArcher et al., 1994; Wadman et al., 1994) and the LIMonly protein LMO2 binds to several partners in haematopoietic cells and in T-cell tumours. By modifying the LIM-domain protein ± protein interactions of LMO2, it might be possible to control the critical speci®c step of tumour neo-vascularization. One interesting LMO2 interaction which could be a drug target is with the transcription factor TAL1/SCL as this protein also has a role in vascular formation (Visvader et al., 1998) . Finally by inhibiting the transcriptional mechanism of neo-vascularization, it should be possible to simultaneously control angiogenesis-related downstream genes, which may be a potent Figure 2 Lmo2 expression in tumour vasculature. Tissues were dissected from normal thymus of an Lmo2+/7 mouse or T-cell tumour-bearing Lmo2+/7 ; p537/7 mice (9 ± 15 weeks old) followed by whole mount X-gal staining and histological sectioning (4 mM). These were counter-stained with nuclear fast red. Blue endothelial staining (b-gal) is evident in the T cell lymphoma sections but little in the normal thymus. Middle section is an abdominal lymph node tumour (T cell lymphoma) and right hand section is from a thymic T-cell lymphoma. en=endothelium. (b) Human lung adenocarcinoma (upper panels) and normal part of lung from the same surgical sample (lower panels) were studied for LMO2 expression. Haematoxylin and eosin (H&E) staining of lung adenocarcinoma showed that cancer cell nests (cells with large nucleus) are surrounded by a vascular network, which is stained with anti-CD31 (pan-endothelial marker, PECAM) (positive=brown colour). Large vessels of normal lung are CD31 positive in the same manner. LMO2 protein is detected in tumour vessels as shown in anti-LMO2 staining of adenocarcinoma vessels, while LMO2 protein is almost undetectable in normal vessels 
ES cell-derived teratocarcinomas were induced by subcutaneous injection of Lmo2+/7 or Lmo27/7 ES cells into nude mice. In total 19 tumours from each implantation were examined. At each point, the number of tumours examined is indicated and the number in which vascular trees (vt) were detected Lmo2 in tumour neo-vascularization Y Yamada et al Figure 3 The development of ES-cell derived vascular networks in subcutaneous teratocarcinomas. Subcutaneous teratocarcinomas were produced in nude mice by implantation of heterozygous Lmo2+/7 or homozygous null Lmo27/7 ES cells. 2610 6 of either Lmo2+/7 or Lmo27/7 ES cells were implanted into both¯anks of nude mice. Subcutaneous tumours were dissected from the recipient mice at 2, 3, 3.5 and 4 weeks (W) after implantation, followed by whole mount X-gal staining and photography (sections and IHC is shown in Figure 4) . Vessels of ES-cell origin are distinguishable from those of host (nude mice) origin by their blue colour after X-gal staining due to the knock-in fusion of lacZ into the Lmo2 gene (Yamada et al., 2000) . ES-derived vascular development is apparent about 2 ± 3 weeks after implantation in Lmo2+/7 ES cell tumours (upper panels) but not in Lmo27/7 ES cell tumours (lower panels). At 3 ± 4 weeks, well developed vascular trees were seen in Lmo2+/7 tumours, whilst there was still no sign of vascular development from Lmo27/7 ES-derived endothelium at 4 weeks. vt=vascular tree method to regulate neo-vascularization and eventually to control tumour growth and metastasis. Alternatively the identity of these downstream gene products may themselves be drug targets.
Materials and methods

ES cells and gene targeted mice
The targeting of the Lmo2 locus in ES cells creating an inframe gene fusion of the lacZ gene with Lmo2 has been described and the mouse strain called previously called KZ26 (Yamada et al., 2000) . As the homozygous null mutation of Lmo2 is embryonic lethal , we maintain the mouse line in the heterozygous state (designated Lmo2 is embryonic lethal , we maintain the mouse line in the heterozygous state (designated Lmo2+/7 ). Both heterozygous Lmo2-targeted ES cells (Lmo2+/7 cells) and homozygous Lmo27/7 targeted ES cells have been described (Yamada et al., 2000) .
Tumour growth
Lmo2+/7 mice were crossed with p537/7 (Harvey et al., 1993) to generate Lmo2+/7 ; p53+/7 which were interbred to generate Lmo2+/7 ; p537/7 .
Teratocarcinomas were produced from ES cells implanted in nude mice. ES cells were grown on neomycin-resistant feeders in the presence of LIF prior to trypsinisation. The washed cells were resuspended in PBS at a concentration of 2610 6 /100 ml. 100 ml of cell suspension was injected subcutaneously into both¯anks of adult MF1 female nude mice. A cohort of mice was used for each of Lmo2+/7 and Lmo27/7 ES cells. Tumours were measured every 4 days with a dial-caliper for decision points on dissection.
Whole mount staining and histology of mouse tissues and tumour samples Organs and tumours were excised from mice and cut into two pieces or into slices to allow maximum penetration of the Xgal reagents. After ®xing in 4% paraformaldehyde solution in phosphate buered saline (PBS) for 45 min at room temperature, samples were subjected to X-gal staining of bgalactosidase activity (resulting from Lmo2-lacZ gene expression) according to the procedure described (Yamada et al., 2000) . For histological studies, samples were post-®xed in 10% (vol/vol) buered formalin for at least 48 h after X-gal staining. The specimens were embedded in paran for sectioning (4 mM). Sections were mounted on microscope slides and counter-stained with nuclear fast red or haematoxylin. CD31 immunohistochemistry was done with MEC 13.3 anti-mouse CD31 (Pharmingen) (12.5 mg/ml) by AvidinBiotin conjugated peroxidase method as described (TanieÁ re et al., 2001) .
Immunohistochemical study of human lung carcinoma
Lung adenocarcinoma and squamous cell carcinomas and matched peripheral part of normal lung were taken from surgical resection specimens and preserved in liquid nitrogen. Frozen sections of 8 mm thickness were prepared from each sample for haematoxylin and eosin staining or immunohistochemistry with anti-CD31 antibody (clone JC/70A, DAKO, Copenhagen, Denmark) used at concentration 100 ng/ml. Immunohistochemistry with anti-LMO2 rabbit polyclonal antibody was carried out at concentration 5 mg/ml. Immunohistochemistry was performed as described by Avidin-Biotin conjugated peroxidase method as described (TanieÁ re et al., 2001) .
